{"certainAgreement":{"otherDetails":"The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"On 29052018 the Sponsor closed the recruitment of the study due to the slow patient accrual. Besides the negative opinion of the EMA recommending the refusal of the marketing authorization for plitidepsin for MM reinforced the decision."},"pointOfContact":{"email":"clinicaltrials@pharmamar.com","organization":"Pharma Mar, S.A.","phone":"+34 918466000","title":"Clinical Developtment, Department of PharmaMar´s Oncology., Business Unit."}}